Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

    Lorusso D (#1), Hilpert F (#2,3), González Martin A (4,5), Rau J (6), Ottevanger P (7), Greimel E (8), Lück HJ (9), Selle F (10), Colombo N (11), Kroep JR (12), Mirza MR (13), Berger R (14), Pardo B (15), Grischke EM (16), Berton-Rigaud D (17), Martinez-Garcia J (18), Vergote I (19), Redondo A (20), Cardona A (21), Bastière-Truchot L (21), du Bois A (22), Kurzeder C (22,23); PENELOPE trial investigators.

    (1) Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
    (2) Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany (affiliation when work was performed).
    (3) Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany.
    (4) Grupo Español de Investigación en Cáncer de Ovario (GEICO) and MD Anderson Cancer Center Spain, Madrid, Spain (affiliation when work was performed).
    (5) Clínica Universidad de Navarra, Madrid, Spain.
    (6) Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany.
    (7) Dutch Gynaecological Oncology Group (DGOG) and Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
    (8) Medical University Graz, Graz, Austria.
    (9) AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Hannover, Germany.
    (10) Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Groupe Hospitalier Diaconesses Croix Saint-Simon and Alliance Pour la Recherche en Cancérologie, Paris, France.
    (11) Mario Negri Gynecologic Oncology (MaNGO) group, IEO, European Institute of Oncology IRCCS, and University of Milan-Bicocca, Milan, Italy.
    (12) DGOG and Department of Medical Oncology, Leids Universitair Medisch Centrum, Leiden, Netherlands.
    (13) Nordic Society of Gynaecological Oncology (NSGO) and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
    (14) AGO-Austria and University Hospital for Gynaecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.
    (15) GEICO and Medical Oncology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
    (16) AGO and University Hospital of Gynecology and Obstetrics, Tübingen, Germany.
    (17) GINECO and Integrated Center for Oncology Nantes-Angers, Nantes, France.
    (18) GEICO and Medical Oncology Service, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain.
    (19) AGO and Leuven Cancer Institute, University Hospital Leuven, Leuven, Belgium.
    (20) GEICO and Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
    (21) F. Hoffmann-La Roche, Basel, Switzerland.
    (22) AGO and Kliniken Essen Mitte, Essen, Germany.
    (23) Department of Gynecology and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
    #Contributed equally

    International Journal of Gynecological Cancer 15 de AGOSTO de 2019

  • Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

    Ray-Coquard I (1), Cibula D (2), Mirza MR (3), Reuss A (4), Ricci C (5), Colombo N (6), Koch H (7), Goffin F (8), González-Martin A (9), Ottevanger PB 10, Baumann K (11), Bjørge L (12), Lesoin A (13), Burges A (14), Rosenberg P (15), Gropp-Meier M (16), Harrela M (17), Harter P (18), Frenel JS (19), Minarik T (20), Pisano C (21), Hasenburg A (22), Merger M (23), du Bois A (18); AGO Study Group-led GCIG/ENGOT Intergroup Consortium.

    (1) GINECO and Medical Oncology Department, Centre Léon Bérard, University Claude Bernard Lyon, Lyon, France.
    (2) AGO and Oncogynecologic Center, Department of Obstetrics and Gynecology, General Faculty Hospital, Charles University of Prague, Prague, Czech Republic.
    (3) NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
    (4) AGO and Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany.
    (5) MITO and Division of Gynecologic Oncology, Department of Women and Children's Health and Public Health, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
    (6) MaNGO and European Institute of Oncology and University of Milan Bicocca, Milan, Italy.
    (7) AGO Austria and Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria.
    (8) BGOG and CHU de Liège, University of Liège, Liège, Belgium.
    (9) GEICO and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
    (10) DGOG and Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
    (11) AGO and Department of Gynecology, Klinikum der Stadt Ludwigshafen GmbH, Ludwigshafen, Germany.
    (12) NSGO and Department of Gynecology, Haukeland Universitetssykehus, Bergen, and Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
    (13) GINECO and Department of Gynecologic Cancer and Medical Oncology, Centre Oscar Lambret, Lille, France.
    (14) AGO and Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany.
    (15) NSGO and Department of Oncology, University Hospital Linköping, Linköping, Sweden.
    (16) AGO and Department of Gynecology and Obstetrics, Oberschwabenklinik, Krankenhaus St. Elisabeth, Ravensburg, Germany.
    (17) NSGO and Department of Gynoncology and Gynecology and Obstetrics, Kymenlaakso Central Hospital, Kotka, Finland.
    (18) AGO and Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
    (19)GINECO and Centre René Gauducheau, Institut de Cancerologie de l'Ouest, Saint Herblain, France.
    (20) NSGO and National Institute of Oncology, Bratislava, Slovakia.
    (21) MITO and Department of Uro-Gynecologic Oncology, Istituto Nazionale per Io Studio e la Cura dei Tumori 'Fondazione G. Pascale' IRCCS, Napoli, Italy.
    (22) AGO and Department of Obstetrics and Gynecology, University Medical Center, Mainz, Germany.
    (23) Oncology Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany.

    International Journal of Cancer 05 de AGOSTO de 2019

  • Joint ENGOT and GOG Foundation requirements for trials with industry partners

    Vergote I (1), Coleman RL (2), Pignata S (3), Bookman MA (4), Marth C (5), Herzog TJ (6), Gonzalez-Martin A (7), Copeland LJ (8); European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation Inc..

    (1) ENGOT/BGOG and University Hospital Leuven, Gynaecological Oncology, Leuven Cancer Institute, Herestraat 49, 3000 Leuven, Belgium, European Union. Electronic address: Ignace.vergote@uz.kuleuven.ac.be.
    (2) GOG-F and Gynecologic Oncology & Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
    (3) ENGOT/MITO Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli, Italy.
    (4) GOG-F and Gynecologic Oncology Therapeutics, Kaiser Permanente San Francisco, San Francisco, USA.
    (5) ENGOT/A-AGO and Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.
    (6) GOG-F and Gynecologic Oncology, University of Cincinnati, Cincinnati, Ohio, USA.
    (7) ENGOT/GEICO and Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain.
    (8) GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA.

    Gynecologic Oncology 01 de AGOSTO de 2019

  • Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

    Garcia Garcia Y (1), de Juan Ferré A (2), Mendiola C (3), Barretina-Ginesta MP (4), Gaba Garcia L (5), Santaballa Bertrán A (6), Bover Barcelo I (7), Gil-Martin M (8), Manzano A (9), Rubio Pérez MJ (10), Romeo Marin M (11), Arqueros Núñez C (12), García-Martínez E (13), Gonzalez Martin A (14).

    (1) Medical Oncology Department, Parc Taulí Hospital Universitari. Institut d'Investigació iInnovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Spain
    (2) Medical Oncology Department, University Hospital Marqués de Valdecilla, Santander, Spain.
    (3) Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
    (4 )Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari Dr Josep Trueta, Girona, Spain.
    (5) Department of Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr Josep Trueta, and Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain.
    (6) Medical Oncology Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
    (7) Medical Oncology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain.
    (8) Medical Oncology Department, Catalan Institute of Oncology-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, Barcelona, Spain.
    (9) Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain.
    (10) Medical Oncology, University Hospital Reina Sofia, Córdoba, Spain.
    (11) Medical Oncology Department, Catalan Institute of Oncology, Badalona - Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain.
    (12) Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
    (13) Hematology and Medical Oncology Service, University Hospital Morales Meseguer, Murcia, Spain.
    (14) Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.

    International Journal of Gynecological Cancer 01 de JULIO de 2019

  • Early-stage mucinous carcinoma (infiltrative type) of the ovary and fertility preservation

    Platero M (1), Espinosa I (1), Vega Suarez V (2), Gonzalez Martin A (3), Chiva L (4)

    (1) Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain.
    (2) Radiology, Clínica Universidad de Navarra, Madrid, Spain.
    (3) Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain.
    (4) Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain

    International Journal of Gynecological Cancer 16 de ABRIL de 2019

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra